Abstract: A method for promoting chronic wound healing is provided, including administering an effective amount of Bletilla formosana (Hayata) Schltr. extract to a subject in need thereof, wherein the effective amount of Bletilla formosana (Hayata) Schltr. extract is 0.01 mg/kg-body weight to 100 mg/kg-body weight, and wherein the chronic wound including diabetic wound and Diabetic Foot Ulcer.

Abstract: A method for inhibiting infection of SARS-CoV-2 in a subject is provided, comprising administering an effective amount of plant extract, wherein the plant extract comprises an alcohol extract of the herbal of Menispermaceae, wherein the herbal of Menispermaceae is Stephania cepharantha or Stephania tetrandra.

Abstract: A method for inhibiting infection of SARS-CoV-2 in a subject is provided, including administering to the subject a compound, wherein the compound comprises Aromoline, Obamegine, Berbamine or Bersavine.

Abstract: A method for inhibiting infection of SARS-CoV-2 in a subject is provided, comprising administering an effective amount of plant extract, wherein the plant extract comprises an alcohol extract of the herbal of Menispermaceae, wherein the herbal of Menispermaceae is Stephania cepharantha or Stephania tetrandra.

Abstract: A method for inhibiting inflammatory in a subject is provided, comprising: administering a pharmaceutical composition comprising an effective amount of 9,11-secosteroids.

Abstract: Disclosed herein are compounds of formula (I), and pharmaceutical compositions comprising the same. The compounds of formula (I) are neutrophilic inflammation inhibitors, thus, they are useful for treatment and/or prophylaxis of inflammatory diseases and/or disorders associated with abnormal activation of neutrophils, such as ARDS, ALI, COPD, lung fibrosis, chronic bronchitis, pulmonary emphysema, ?-1 anti-trypsin deficiency, cystic fibrosis, idiopathic pulmonary fibrosis, liver injury, steatohepatitis, liver fibrosis, damages caused by ischemia and reperfusion, myocardial infarction, shock, stroke, and organ transplantation, ulcerative cholitis, vasculitis, SLE, sepsis, SIRS, arthritis, psoriasis, atopic dermatitis, and inflammatory skin diseases.

Abstract: Disclosed herein are compounds of formula (I), and pharmaceutical compositions comprising the same. The compounds of formula (I) are neutrophilic inflammation inhibitors, thus, they are useful for treatment and/or prophylaxis of inflammatory diseases and/or disorders associated with abnormal activation of neutrophils, such as ARDS, ALI, COPD, lung fibrosis, chronic bronchitis, pulmonary emphysema, ?-1 anti-trypsin deficiency, cystic fibrosis, idiopathic pulmonary fibrosis, liver injury, steatohepatitis, liver fibrosis, damages caused by ischemia and reperfusion, myocardial infarction, shock, stroke, and organ transplantation, ulcerative cholitis, vasculitis, SLE, sepsis, SIRS, arthritis, psoriasis, atopic dermatitis, and inflammatory skin diseases.

Abstract: Compositions comprising one or more nanoparticles, wherein the nanoparticles encapsulate fluorescence dyes are disclosed. In one embodiment, the nanoparticle comprises triterpene. In another embodiment, the nanoparticle comprises triterpene and fatty ester. Methods for performing a diagnostic or a therapeutic procedure comprising administering to a subject an effective amount of the compositions of the present invention or carbocyanine dyes are also provided.